Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A - Young, G.; Mahlangu, J.; Kulkarni, R.; Nolan, B.; Liesner, R.; Pasi, J.; Barnes, C.; Neelakantan, S.; Gambino, G.; Cristiano, L. M.; Pierce, G. F.; Allen, G. (Journal of thrombosis and haemostasis, 2015)
Keywords: Age Factors; Antibodies, Neutralizing - blood; Australia; Child; Child, Preschool; children; China; Coagulants - administration & dosage; Coagulants - adverse effects; Coagulants - immunology; Coagulants - pharmacokinetics; coagulation factor VIII; Drug Administration Schedule; Europe; Factor VIII - administration & dosage; Factor VIII - adverse effects; Factor VIII - immunology; Factor VIII - pharmacokinetics; Female; Half-Life; Hemarthrosis - blood; Hemarthrosis - diagnosis; Hemarthrosis - drug therapy; Hemarthrosis - prevention & control; Hemophilia A - blood; Hemophilia A - diagnosis; Hemophilia A - drug therapy; Hemophilia A - prevention & control; hemophilia A; Humans; Immunoglobulin Fc Fragments - administration & dosage; Immunoglobulin Fc Fragments - adverse effects; Immunoglobulin Fc Fragments - immunology; Infusions, Intravenous; Male; North America; prophylaxis; recombinant fusion proteins; Recombinant Fusion Proteins - administration & dosage; Recombinant Fusion Proteins - adverse effects; Recombinant Fusion Proteins - immunology; Recombinant Fusion Proteins - pharmacokinetics; Risk Factors; Severity of Illness Index; South Africa; Treatment Outcome; South Africa; Australia; North America; China; Europe; hemophilia A; recombinant fusion proteins; coagulation factor VIII; children; prophylaxis